Sandler Capital Management Purchases 9,290 Shares of Hologic, Inc. $HOLX

Key Points

• Sandler Capital Management increased its holdings in Hologic, Inc. by 20.9% during the first quarter, bringing its total shares to 53,824 valued at approximately $3.325 million.
• Multiple institutional investors have shown interest in Hologic, with a collective ownership of nearly 94.73% of the stock, indicating robust institutional confidence in the company.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Hologic's stock, with a price target set at $78.00, reflecting positive growth expectations.

Sandler Capital Management raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,824 shares of the medical equipment provider's stock after purchasing an additional 9,290 shares during the quarter. Sandler Capital Management's holdings in Hologic were worth $3,325,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HOLX. Zions Bancorporation National Association UT bought a new position in Hologic during the first quarter valued at $34,000. Allworth Financial LP lifted its position in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in Hologic during the first quarter valued at $42,000. Larson Financial Group LLC lifted its position in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 722 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in Hologic during the fourth quarter valued at $49,000. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. Wall Street Zen raised shares of Hologic from a "hold" rating to a "buy" rating in a research note on Sunday. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research note on Monday, August 18th. Evercore ISI increased their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and increased their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their target price for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Stock Up 0.3%

NASDAQ HOLX traded up $0.18 during trading on Tuesday, reaching $66.72. 1,186,914 shares of the company's stock traded hands, compared to its average volume of 1,570,787. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The firm has a market cap of $14.84 billion, a price-to-earnings ratio of 27.68, a price-to-earnings-growth ratio of 2.42 and a beta of 0.57. The company's 50 day simple moving average is $66.40 and its two-hundred day simple moving average is $62.63. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.